PERFORMANCE / SINGLE
PT-141
10MGImportant medical and research notice
This content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.
Research Overview
A melanocortin receptor agonist (bremelanotide) studied in central-nervous-system signalling research.
Available Strengths
- 10MG (P41)
Research Protocol
Reference schedule
| Period | Dose | U-100 units | Volume |
|---|---|---|---|
| Weeks 1–8 | 0.5 mg | 15 | 0.15 mL |
| Weeks 9–12 | 1 mg | 30 | 0.3 mL |
| Weeks 13–16 | 1.5 mg | 45 | 0.45 mL |
Reconstitution
Water volume3 mLConcentration3.33 mg/mLAdministrationSubcutaneousFrequencyOnce dailyCycle length8–16 weeks with gradual titration in the reference protocol.
≈3.33 mg/mL once reconstituted
- Draw 3.0 mL of bacteriostatic water per 10 mg vial.
- Inject slowly along the vial wall; swirl gently until dissolved.
Research context
Targets MC3R/MC4R; the cited research links MC4R activation to increased dopamine release in brain reward and arousal regions.
Storage
−20°C, dry and dark. 2–8°C, use within ~30 days, avoid freeze-thaw cycles.
Research Notes
- For educational and research reference only. Not medical advice and not intended for unsupervised human use.
- The approved bremelanotide product is a fixed autoinjector formulation and is not interchangeable with this research vial.
References
Source reference: PeptideDosages.com · 2026-08-18 · Exact strength match with the cited source